For the year ending 2025-12-31, INKT had $8,783,300 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -12,494,260 |
| Depreciation | 181,745 |
| Share-based compensation | 2,673,997 |
| Loss on disposal of assets | -169,800 |
| Change in fair value of related party note | 154,832 |
| Interest accrued on related party note | 100,000 |
| Prepaid expenses | 29,788 |
| Accounts payable | 689,710 |
| Accrued liabilities and other current liabilities | 720,196 |
| Other operating assets and liabilities | -1,908,600 |
| Net cash used in operating activities | -5,925,168 |
| Net proceeds from sale of equity | 14,454,941 |
| Purchase of treasury shares to satisfy tax withholdings | 173,353 |
| Proceeds from employee stock purchases and option exercises | 440,309 |
| Net cash provided by financing activities | 14,721,897 |
| Effect of exchange rate changes on cash | -13,429 |
| Net increase in cash and cash equivalents | 8,783,300 |
| Cash and cash equivalents, beginning of period | 4,577,040 |
| Cash and cash equivalents, end of period | 13,360,340 |
MiNK Therapeutics, Inc. (INKT)
MiNK Therapeutics, Inc. (INKT)